Association of MRD response with outcome in patients with BCP-ALL after treatment with blinatumomab (full analysis set). Kaplan-Meier plots of OS (A), RFS (B), and DoR (C) in patients with hematologic CR/CRh and evaluable MRD assessments by MRD response (MRD-evaluable patients, n = 90). NE, not estimable.